WO1998002190A3 - Cationic amphiphile/dna complexes - Google Patents

Cationic amphiphile/dna complexes Download PDF

Info

Publication number
WO1998002190A3
WO1998002190A3 PCT/US1997/012105 US9712105W WO9802190A3 WO 1998002190 A3 WO1998002190 A3 WO 1998002190A3 US 9712105 W US9712105 W US 9712105W WO 9802190 A3 WO9802190 A3 WO 9802190A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
gene therapy
cationic
therapeutic compositions
molecules
Prior art date
Application number
PCT/US1997/012105
Other languages
French (fr)
Other versions
WO1998002190A2 (en
WO1998002190A9 (en
Inventor
Ronald K Scheule
Rebecca G Bagley
Simon J Eastman
Seng H Cheng
John Marshall
Nelson S Yew
David J Harris
Edward R Lee
Craig S Siegel
Chau-Dung Chang
C Shirley Hubbard
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to EP97933396A priority Critical patent/EP0954338A2/en
Priority to AU36590/97A priority patent/AU738083B2/en
Priority to JP10506183A priority patent/JP2000516209A/en
Publication of WO1998002190A2 publication Critical patent/WO1998002190A2/en
Publication of WO1998002190A3 publication Critical patent/WO1998002190A3/en
Publication of WO1998002190A9 publication Critical patent/WO1998002190A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.
PCT/US1997/012105 1996-07-12 1997-07-11 Cationic amphiphile/dna complexes WO1998002190A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97933396A EP0954338A2 (en) 1996-07-12 1997-07-11 Cationic amphiphile/dna complexes
AU36590/97A AU738083B2 (en) 1996-07-12 1997-07-11 Cationic amphiphile/ DNA complexes
JP10506183A JP2000516209A (en) 1996-07-12 1997-07-11 Cationic amphiphile / DNA complex

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/679,514 1996-07-12
US08/679,514 US5948767A (en) 1994-12-09 1996-07-12 Cationic amphiphile/DNA complexes

Publications (3)

Publication Number Publication Date
WO1998002190A2 WO1998002190A2 (en) 1998-01-22
WO1998002190A3 true WO1998002190A3 (en) 1998-10-22
WO1998002190A9 WO1998002190A9 (en) 1998-12-17

Family

ID=24727216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012105 WO1998002190A2 (en) 1996-07-12 1997-07-11 Cationic amphiphile/dna complexes

Country Status (6)

Country Link
US (1) US5948767A (en)
EP (1) EP0954338A2 (en)
JP (1) JP2000516209A (en)
AU (1) AU738083B2 (en)
CA (1) CA2260034A1 (en)
WO (1) WO1998002190A2 (en)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
JP3229528B2 (en) * 1994-11-22 2001-11-19 松下電器産業株式会社 Dielectric porcelain and dielectric resonator
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
AU750803B2 (en) 1997-10-29 2002-07-25 University Of Pittsburgh Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
US6043390A (en) * 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
DK1129064T3 (en) * 1998-11-12 2008-04-28 Invitrogen Corp transfection
US20020103359A1 (en) * 1999-12-07 2002-08-01 Gregory Donoho Novel human membrane proteins and polynucleotides encoding the same
US6570003B1 (en) * 2001-01-09 2003-05-27 Lexion Genetics Incorporated Human 7TM proteins and polynucleotides encoding the same
US6448388B1 (en) 2000-08-16 2002-09-10 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
US20050153323A1 (en) * 2000-07-28 2005-07-14 Yi Hu Novel human proteases and polynucleotides encoding the same
US20080003673A1 (en) * 1999-09-02 2008-01-03 Alejandro Abuin Novel human proteases and polynucleotides encoding the same
US6649399B2 (en) 1999-12-09 2003-11-18 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
US6716614B1 (en) 1999-09-02 2004-04-06 Lexicon Genetics Incorporated Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof
US20030050464A1 (en) * 2000-07-28 2003-03-13 Yi Hu Novel human proteases and polynucleotides encoding the same
US7374933B2 (en) * 2000-04-12 2008-05-20 Lexicon Pharmaceuticals, Inc. Human metalloprotease and polynucleotides encoding the same
US6790660B1 (en) * 2001-09-18 2004-09-14 Lexicon Genetics Incorporated Human kielin-like proteins and polynucleotides encoding the same
US20030028907A1 (en) * 2001-07-03 2003-02-06 Walke D. Wade Novel human kielin-like proteins and polynucleotides encoding the same
US6867291B1 (en) * 2000-09-15 2005-03-15 Lexicon Genetics Incorporated Human hemicentin proteins and polynucleotides encoding the same
US6511840B1 (en) 2000-06-15 2003-01-28 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US6734010B2 (en) * 2001-05-09 2004-05-11 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6444456B1 (en) 2000-03-10 2002-09-03 Lexicon Genetics Incorporated Human G-coupled protein receptor kinases and polynucleotides encoding the same
US6586230B1 (en) 2000-10-27 2003-07-01 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6797510B1 (en) 2001-05-24 2004-09-28 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US6720173B1 (en) 1999-11-08 2004-04-13 Lexicon Genetics Incorporated Human kinase protein and polynucleotides encoding the same
US6593125B2 (en) 2000-11-20 2003-07-15 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6541252B1 (en) 2000-05-19 2003-04-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6841377B1 (en) 2001-06-13 2005-01-11 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6900045B2 (en) * 2000-08-31 2005-05-31 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US6750054B2 (en) * 2000-05-18 2004-06-15 Lexicon Genetics Incorporated Human semaphorin homologs and polynucleotides encoding the same
US20080213878A1 (en) * 1999-10-19 2008-09-04 Gregory Donoho Novel human membrane proteins and polynucleotides encoding the same
EP1242588A2 (en) * 1999-11-12 2002-09-25 Lexicon Genetics Incorporated Human proteins with homology to carboxypeptidases and polynucleotides encoding the same
AU1920601A (en) * 1999-11-19 2001-05-30 Lexicon Genetics Incorporated Novel human secreted proteins and polynucleotides encoding the same
EP1240187A2 (en) * 1999-12-07 2002-09-18 Lexicon Genetics Incorporated Novel human kinase proteins and polynucleotides encoding the same
WO2001042477A1 (en) * 1999-12-13 2001-06-14 Lexicon Genetics Incorporated Novel human transferase proteins and polynucleotides encoding the same
WO2001046407A1 (en) * 1999-12-22 2001-06-28 Lexicon Genetics Incorporated Polynucleotides encoding human protease homologs
US20020045743A1 (en) * 1999-12-22 2002-04-18 Walke D. Wade Novel human membrane proteins and polynucleotides encoding the same
CA2402360A1 (en) * 2000-01-06 2001-07-12 Lexicon Genetics Incorporated Novel human proteases and polynucleotides encoding the same
CA2397789C (en) 2000-01-18 2010-10-19 Lexicon Genetics Incorporated Novel human kinase protein and polynucleotides encoding the same
US20020077464A1 (en) * 2000-01-26 2002-06-20 Turner C. Alexander Novel human neurexin-like proteins and polynucleotides encoding the same
CA2398791A1 (en) * 2000-01-28 2001-08-02 Lexicon Genetics Incorporated Human membrane proteins and polynucleotides encoding the same
CA2398087A1 (en) * 2000-01-28 2001-12-13 Lexicon Genetics Incorporated Novel human enzymes and polynucleotides encoding the same
JP2003529348A (en) * 2000-02-04 2003-10-07 レキシコン・ジェネティクス・インコーポレーテッド Novel human membrane proteins and polynucleotides encoding them
ATE366315T1 (en) * 2000-02-04 2007-07-15 Lexicon Genetics Inc HUMAN ENZYMES AND POLYNUCLEOTIDES ENCODING THEREOF
JP2003522530A (en) 2000-02-11 2003-07-29 レキシコン・ジェネティクス・インコーポレーテッド Novel human protease and polynucleotide encoding the protease
AU2001238503A1 (en) 2000-02-17 2001-08-27 Lexicon Genetics Incorporated Novel human thrombospondin repeat proteins and polynucleotides encoding the same
AU2001245370A1 (en) * 2000-02-29 2001-09-12 Lexicon Genetics Incorporated Novel human transferase proteins and polynucleotides encoding the same
CA2401645A1 (en) * 2000-02-29 2001-09-07 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
US20020082405A1 (en) * 2000-03-06 2002-06-27 Gregory Donoho Novel human transporter proteins and polynucleotides encoding the same
JP2004500107A (en) * 2000-03-13 2004-01-08 レキシコン・ジェネティクス・インコーポレーテッド Novel human phospholipase and polynucleotide encoding the same
CA2403636A1 (en) * 2000-03-20 2001-09-27 Lexicon Genetics Incorporated Human secreted proteins and polynucleotides encoding the same
AU4956901A (en) * 2000-03-28 2001-10-08 Lexicon Genetics Inc Novel human 7tm proteins and polynucleotides encoding the same
EP1272634A1 (en) 2000-04-03 2003-01-08 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
AU5719501A (en) 2000-04-25 2001-11-07 Lexicon Genetics Inc Novel human kinase proteins and polynucleotides encoding the same
AU2001259174A1 (en) * 2000-04-28 2001-11-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
WO2001088134A2 (en) * 2000-05-12 2001-11-22 Lexicon Genetics Incorporated Novel human lipocalin homologs and polynucleotides encoding the same
WO2001090179A2 (en) * 2000-05-23 2001-11-29 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
US6790667B1 (en) * 2000-05-30 2004-09-14 Lexicon Genetics Incorporated Human mitochondrial proteins and polynucleotides encoding the same
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP1297134A2 (en) * 2000-06-27 2003-04-02 Lexicon Genetics Incorporated Novel human gaba receptors and polynucleotides encoding the same
WO2002008396A2 (en) * 2000-07-21 2002-01-31 Incyte Genomics, Inc. Human proteases
US6887685B1 (en) 2000-07-25 2005-05-03 Lexicon Genetics Incorporated Human thymosin protein and polynucleotides encoding the same
US20020076780A1 (en) * 2000-08-16 2002-06-20 Turner C. Alexander Novel human ion channel proteins and polynucleotides encoding the same
JP2004506447A (en) * 2000-08-22 2004-03-04 レキシコン・ジェネティクス・インコーポレーテッド Novel human 7TM protein and polynucleotide encoding the same
ATE334208T1 (en) * 2000-08-22 2006-08-15 Lexicon Genetics Inc HUMAN PROTEASES AND POLYNUCLEOTIDES ENCODING THEM
WO2002020753A2 (en) * 2000-09-01 2002-03-14 Lexicon Genetics Incorporated Human gaba transporter protein and polynucleotides encoding the same
WO2002026981A2 (en) * 2000-09-27 2002-04-04 Lexicon Genetics Incorporated Human protease inhibitor proteins and polynucleotides encoding the same
WO2002026980A2 (en) 2000-09-27 2002-04-04 Lexicon Genetics Incorporated Human ion-exchanger proteins and polynucleotides encoding t he same
US6777232B1 (en) 2000-10-02 2004-08-17 Lexicon Genetics Incorporated Human membrane proteins and polynucleotides encoding the same
WO2002031129A2 (en) 2000-10-12 2002-04-18 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US7001763B1 (en) 2000-10-17 2006-02-21 Lexicon Genetics Incorporated Human semaphorin proteins and polynucleotides encoding the same
CA2427113A1 (en) * 2000-10-27 2002-09-12 Lexicon Genetics Incorporated Novel human 7tm proteins and polynucleotides encoding the same
EP1330524A2 (en) * 2000-10-30 2003-07-30 Lexicon Genetics Incorporated Novel human 7tm proteins and polynucleotides encoding the same
CA2427828A1 (en) * 2000-11-01 2002-05-10 Lexicon Genetics Incorporated Novel human proteases and polynucleotides encoding the same
JP2004535154A (en) * 2000-11-15 2004-11-25 レキシコン・ジェネティクス・インコーポレーテッド Novel human secretory protein and polynucleotide encoding the same
EP1341906A2 (en) * 2000-12-11 2003-09-10 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
AU3264202A (en) * 2000-12-12 2002-06-24 Lexicon Genetics Inc Novel human kinases and polynucleotides encoding the same
US6583269B1 (en) * 2000-12-18 2003-06-24 Lexicon Genetics Incorporated Human protease inhibitor and polynucleotides encoding the same
WO2002050271A2 (en) * 2000-12-20 2002-06-27 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
US6852844B1 (en) * 2000-12-20 2005-02-08 Lexicon Genetics Incorporated Human protocadherin proteins and polynucleotides encoding the same
AU2002246858A1 (en) * 2000-12-27 2002-08-06 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
AU2001297533A1 (en) * 2000-12-28 2002-09-12 Lexicon Genetics Incorporated Novel human ion channel-related proteins and polynucleotides encoding the same
US20020115844A1 (en) * 2001-01-05 2002-08-22 Yu Xuanchuan Sean Novel human lipase and polynucleotides encoding the same
CA2434896A1 (en) * 2001-01-23 2002-08-01 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
US20020115846A1 (en) * 2001-01-24 2002-08-22 Xuanchuan (Sean) Yu Novel human lipase and polynucleotides encoding the same
US20020127674A1 (en) * 2001-02-02 2002-09-12 Xuanchuan Yu Novel human transporter protein and polynucleotides encoding the same
CA2473197A1 (en) * 2001-02-20 2002-08-29 Lexicon Genetics Incorporated Novel human protease and polynucleotides encoding the same
JP3929250B2 (en) * 2001-03-08 2007-06-13 株式会社ルネサステクノロジ Semiconductor device
JP2004535781A (en) * 2001-03-12 2004-12-02 レキシコン・ジェネティクス・インコーポレーテッド Novel human EFG family protein and polynucleotide encoding the same
WO2002072774A2 (en) * 2001-03-12 2002-09-19 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
AU2002245593A1 (en) * 2001-03-12 2002-09-24 Lexicon Genetics Incorporated Novel human dectin proteins and polynucleotides encoding the same
US6994995B1 (en) * 2001-03-16 2006-02-07 Lexicon Genetics Incorporated Human synaptotagmin and polynucleotides encoding the same
WO2002074932A2 (en) 2001-03-20 2002-09-26 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
JP2004528841A (en) 2001-04-06 2004-09-24 レキシコン・ジェネティクス・インコーポレーテッド Novel human kinase and polynucleotide encoding it
EP1383879A4 (en) 2001-04-06 2005-05-11 Lexicon Genetics Inc Novel human kinases and polynucleotides encoding the same
US6644173B2 (en) * 2001-04-11 2003-11-11 Keuring, Incorporated Beverage filter cartridge holder
WO2002083706A1 (en) * 2001-04-16 2002-10-24 Lexicon Genetics Incorporated Nucleic acid encoding a human adenylosuccinate synthetase
US20030166893A1 (en) * 2001-04-30 2003-09-04 Yi Hu Novel human nuclear transporters and polynucleotides encoding the same
EP1383480A4 (en) * 2001-04-30 2006-05-24 Targeted Genetics Corp Lipid-comprising drug delivery complexes and methods for their production
WO2002097095A1 (en) * 2001-05-25 2002-12-05 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
EP1461425B1 (en) 2001-05-29 2008-02-13 Lexicon Pharmaceuticals, Inc. Novel human hydroxylases and polynucleotides encoding the same
EP1406645A4 (en) * 2001-06-14 2005-02-16 Lexicon Genetics Inc Novel human transporter proteins and polynucleotides encoding the same
WO2003016481A2 (en) * 2001-08-14 2003-02-27 Lexicon Genetics Incorporated Novel human collagen proteins and polynucleotides encoding the same
AUPR894201A0 (en) * 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
AU2003216288B2 (en) 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
JP4868739B2 (en) * 2002-05-06 2012-02-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド Nucleic acid delivery methods
JP3447009B1 (en) * 2002-10-29 2003-09-16 實 平垣 Construct structure and method for producing the same
ES2407859T3 (en) 2004-09-13 2013-06-14 Genzyme Corporation Multimeric constructions.
US7312079B1 (en) 2005-10-06 2007-12-25 Lexicon Pharmaceuticals, Inc. Variants of FAM3C
US20080004410A1 (en) * 2006-06-30 2008-01-03 Yu-Chin Lai Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same
GB2452765A (en) * 2007-09-14 2009-03-18 Dooworks Fz Co Combining multiple image streams by reducing the colour depth of each bit stream combining them onto a single stream
FR2925491B1 (en) * 2007-12-19 2010-09-03 Oz Biosciences Sas NEW CLASSES OF CATIONIC LIPIDS FOR THE TRANSPORT OF ACTIVE AGENTS IN CELLS
WO2009102427A2 (en) 2008-02-11 2009-08-20 Rxi Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010075010A2 (en) 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
CN102985548B (en) * 2009-05-16 2016-10-26 崔坤元 For deliver treatment molecule comprise cationic amphiphilic thing and the compositions of auxiliary lipid
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc Reduced size self-delivering rnai compounds
JP6060071B2 (en) 2010-03-24 2017-01-11 アールエックスアイ ファーマシューティカルズ コーポレーション RNA interference in skin and fibrosis applications
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
KR102008787B1 (en) * 2013-05-23 2019-08-08 압타바이오 주식회사 Gene Delivery System Comprising a New Cationic Lipid
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
EP3116597A1 (en) * 2014-03-13 2017-01-18 The Secretary of State for Health Antimicrobial conjugates, method for production and uses thereof
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CN106572974B (en) 2014-07-15 2021-04-23 生命技术公司 Compositions and methods having lipid aggregates for efficient delivery of molecules to cells
KR102506169B1 (en) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CA2991598A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
CN105111089B (en) * 2015-09-07 2017-05-10 南京华威医药科技开发有限公司 Bixalomer intermediate
JP2018531037A (en) 2015-10-19 2018-10-25 アールエックスアイ ファーマシューティカルズ コーポレーション Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016024A1 (en) * 1990-04-19 1991-10-31 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1993005162A1 (en) * 1991-08-28 1993-03-18 The University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
WO1996017823A1 (en) * 1994-12-05 1996-06-13 Rhone-Poulenc Rorer S.A. Lipopolyamines as transfection agents and pharmaceutical uses thereof
WO1996018372A2 (en) * 1994-12-09 1996-06-20 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
WO1997029118A1 (en) * 1996-02-05 1997-08-14 Transgene S.A. Lipopolyamine compound, pharmaceutical composition and nucleic acid transfer vector containing same, and preparation method
WO1997031934A2 (en) * 1996-02-29 1997-09-04 Chemicon Laboratories Gmbh Novel metabolizable lipopolyamines, their preparation and their use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS617292A (en) * 1984-06-20 1986-01-13 Japan Atom Energy Res Inst Method for producing estracyt compound bonded with carcinostatic agent
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4971803A (en) * 1985-04-08 1990-11-20 California Institute Of Technology Lamellar vesicles formed of cholesterol derivatives
WO1988000824A1 (en) * 1986-07-28 1988-02-11 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2645866B1 (en) * 1989-04-17 1991-07-05 Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
CA2037478A1 (en) * 1990-03-05 1991-09-06 Richard Gregory Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
EP0490379A3 (en) * 1990-12-13 1992-06-24 BERLIN-CHEMIE Aktiengesellschaft Diamino acid derivatives and pharmaceutical compositions
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5705655A (en) * 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
DK0688333T3 (en) * 1993-03-10 1999-02-08 Magainin Pharma Steroid derivatives, pharmaceutical compositions containing them and their use as antibiotics or disinfectants
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
CA2176714A1 (en) * 1993-11-24 1995-06-01 Timothy D. Heath Amphiphilic derivatives of piperazine
NZ276975A (en) * 1993-11-24 1998-04-27 Megabios Corp Guanidine based amphiphiles and their use in liposomes for delivering genetic material intracellularly
JPH09508099A (en) * 1993-12-20 1997-08-19 ユニヴェルシテ リブル ドゥ ブリュッセル Compound capable of introducing at least one molecule into a cell
AU1919295A (en) * 1994-02-14 1995-08-29 Indiana University Foundation Aminophospholipid compositions and uses thereof
WO1995024222A1 (en) * 1994-03-07 1995-09-14 University Of Medicine & Dentistry Of New Jersey Cyclic polycationic polymer-oligonucleotide conjugates and methods for preparing same
US5670347A (en) * 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1996020208A2 (en) * 1994-12-28 1996-07-04 Max-Delbrück-Centrum für Molekulare Medizin New cholesterol derivative for liposomal gene transfer
FR2730637B1 (en) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
FR2732895B1 (en) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTING AGENT, AS A VACCINE ADDITIVE, OR AS A MEDICINAL PRODUCT
US6756054B1 (en) * 1996-05-24 2004-06-29 Ic-Vec Limited Polycationic sterol derivatives as transfection agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016024A1 (en) * 1990-04-19 1991-10-31 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1993005162A1 (en) * 1991-08-28 1993-03-18 The University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
WO1996017823A1 (en) * 1994-12-05 1996-06-13 Rhone-Poulenc Rorer S.A. Lipopolyamines as transfection agents and pharmaceutical uses thereof
WO1996018372A2 (en) * 1994-12-09 1996-06-20 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
WO1997029118A1 (en) * 1996-02-05 1997-08-14 Transgene S.A. Lipopolyamine compound, pharmaceutical composition and nucleic acid transfer vector containing same, and preparation method
WO1997031934A2 (en) * 1996-02-29 1997-09-04 Chemicon Laboratories Gmbh Novel metabolizable lipopolyamines, their preparation and their use

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BEHR ET AL.: "Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA", PROC. NATL. ACAD. SCI., vol. 86, 1989, pages 6982 - 6986, XP002057565 *
BENNET ET AL.: "Cholesterol Enhances Cationic Liposome-Mediated DNA Transfection of Human Respiratory Epithelial Cells", BIOSCIENCE REPORT, vol. 15, no. 1, 1995, pages 47 - 53, XP002057562 *
EGILMEZ ET AL.: "Evaluation and Optimization of Different Cationic Liposome Formulations for in Vivo Gene Transfer", BIOCHEM. BIOPHYS. RES. COMM., vol. 221, 1996, pages 169 - 173, XP002057564 *
FARHOOD ET AL.: "Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity", BIOCHEM. BIOPHYS. ACTA, vol. 1111, no. 2, 1992, pages 239 - 246, XP002058083 *
GUO ET AL.: "CATIONIC LIPOSOMES CONTAINING NONCYTOTOXIC PHOSPHOLIPID AND CHOLESTEROL DERIVATIVES", J. LIPOSOME RES., vol. 3, no. 1, 1993, pages 51 - 70, XP000349734 *
LEE ET AL.: "Detailed Analysis of Structures and Formulations of Cationic Lipids for Efficient Gene Transfer to the Lung", HUMAN GENE THER., vol. 7, no. 14, 1996, pages 1701 - 1717, XP002057569 *
MORADPOUR D ET AL: "EFFICIENT GENE TRANSFER INTO MAMMALIAN CELLS WITH CHOLESTERYL-SPERMIDINE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 221, no. 1, 5 April 1996 (1996-04-05), pages 82 - 88, XP000608431 *
VIGNERON ET AL.: "Guanidinium-cholesterol cationic lipids: Efficient vectors for the transfection of eukaryotic cells", PROC. NATL. ACAD. SCI., vol. 93, 1996, pages 9682 - 9686, XP002057570 *

Also Published As

Publication number Publication date
AU738083B2 (en) 2001-09-06
CA2260034A1 (en) 1998-01-22
US5948767A (en) 1999-09-07
WO1998002190A2 (en) 1998-01-22
JP2000516209A (en) 2000-12-05
AU3659097A (en) 1998-02-09
EP0954338A2 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
WO1998002190A3 (en) Cationic amphiphile/dna complexes
WO1996018372A3 (en) Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
DE69832293T2 (en) PREPARATIONS FOR THE DELIVERY OF NEGATIVELY LOADED MOLECULES
AU707571B2 (en) Composition containing nucleic acids, preparation and uses
CA2270396C (en) Cationic reagents for transfection
US7553830B2 (en) Compositions for the delivery of negatively charged molecules
JP2007505954A5 (en)
WO1997011682A3 (en) Emulsion and micellar formulations for the delivery of biologically active substances to cells
DE69505677T2 (en) LIPOSOMAL ADMINISTRATION SYSTEM FOR BIOLOGICALLY ACTIVE SUBSTANCES
AU7854791A (en) Cationic lipids for intracellular delivery of biologically active molecules
DE69636032D1 (en) PLASMIDE FOR THE ADMINISTRATION OF NUCLEIC ACIDS AND METHOD OF USE
AU2002256873A1 (en) Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
US9050373B2 (en) Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
AU2008230379B2 (en) Prompt nucleic acid delivery carrier composition
NZ584841A (en) Nucleic acid complex and nucleic acid delivery composition
Chiou et al. In vivo gene therapy via receptor-mediated dna delivery
KR100448298B1 (en) Glucocotricoid enhancement of gene expression
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
WO1999065461A3 (en) Cationic amphiphile micellar complexes
DE10037861A1 (en) Composition for treating malignant disease, useful especially for cervical carcinoma, contains agent that inhibits activity of nucleolin
EP2060262B1 (en) Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc
WO2002028439A2 (en) Transferrin-polycation/dna complexes for the systemic treatment of tumour diseases using cytotoxic proteins
EP1724254A2 (en) Novel compositions for the delivery of negatively charged molecules
MXPA00001855A (en) Novel compositions for the delivery of negatively charged molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

COP Corrected version of pamphlet

Free format text: PAGES 1/23-23/23, DRAWINGS, REPLACED BY NEW PAGES 1/23-23/23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 1997933396

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2260034

Country of ref document: CA

Ref country code: CA

Ref document number: 2260034

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997933396

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997933396

Country of ref document: EP